The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach
Open accessAbstract
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. As the applicability of OLT is nowadays limited by organ shortage, major liver resections—even in patients with underlying chronic liver disease—are adopted increasingly into clinical practice. Against the background of the oftentimes present chronical liver disease, locoregional therapies have also gained increasing significance. These strategies range from radiofrequency ablation and trans-arterial chemoembolization to selective internal radiation therapy and are employed in both curative and palliative intent, individually, as a bridging to transplant or in combination with liver resection. The choice of the appropriate treatment, or combination of treatments, should consider the tumor stage, the function of the remaining liver parenchyma, the future liver remnant volume and the patient’s general condition. This review aims to address the topic of multimodal treatment strategies in HCC, highlighting a multidisciplinary treatment approach to further improve outcome in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · cited 3×
“7 months, respectively) were observed [99].”
BackgroundCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · cited 1×
“However, the adjuvant application of Sorafenib after LR or ablation did not lead to an improved median recurrence-free survival in comparison to the placebo in previous reports [124].”
ResultResection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879 · cited 2×
“In the face of the high probability of tumor recurrence in the cirrhotic liver, adjuvant treatment after liver-directed procedures to reduce this dysplastic potential seems like a reasonable suggestion [30,31,123].”
BackgroundLin, S.-M., Lin, C.-J., Lin, C.-C., Hsu, C.-W., & Chen, Y.-C. (2005) · Gut · doi:10.1136/gut.2004.045203 · Cited by 592 · cited 1×
“PEI ethanol injection causes coagulation necrosis • only limited role in HCC treatment today • highest efficacy in HCC <2 cm [50] • moderate cost, simple, attractive for developing regions [49] • feasible in cirrhosis [49] • well-tolerated [50] • heterogenous intra-tumoral distribution, especially in the presence of s…”
BackgroundPompili, M., Saviano, A., de Matthaeis, N., Cucchetti, A., Ardito, F., Federico, B., Brunello, F., Pinna, A. D., Giorgio, A., Giulini, S. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.009 · Cited by 285
Cited by
Álvarez-Mercado, A. I., Caballeria-Casals, A., Rojano-Alfonso, C., Chávez-Reyes, J., Micó-Carnero, M., Sanchez-Gonzalez, A., Casillas-Ramírez, A., Gracia-Sancho, J., & Peralta, C. (2021) · Biomedicines · doi:10.3390/biomedicines9091158 · Cited by 12
Metadata
- Authors
- Lurje, I., Czigany, Z., Bednarsch, J., Roderburg, C., Isfort, P., Neumann, U. P., & Lurje, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-03-22
- Volume
- 20
- Issue
- 6
- Pages
- 1465
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2924375615
- Cited by
- 229
- References
- 8
- FWCI
- 18.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach. https://app.cochat.ai/papers/10.3390/ijms20061465
- The paper
- Lurje, I., Czigany, Z., Bednarsch, J., Roderburg, C., Isfort, P., Neumann, U. P., & Lurje, G. (2019). Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20061465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.